{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:01Z","timestamp":1794018541568,"version":"4.8.0"},"reference-count":223,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,6,1]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor (CAR) T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.<\/jats:p>","DOI":"10.1136\/jitc-2020-000734","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T06:35:21Z","timestamp":1594622121000},"page":"e000734","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":42,"title":["The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01998971","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03158688","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02874742","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02252172","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02195479","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03012880","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03277105","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03412565","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03901963","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03346135","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01239797","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02654132","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01478048","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03155100","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01335399","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02495922","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01668719","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03275285","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02990338","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03319667","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03617731","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03361748","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03601078","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03651128","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04196491","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03090659","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03548207","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03758417","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03502577","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03309111","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03445663","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03399799","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03275103","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03145181","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03269136","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03287908","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03761108","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04083534","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03287908","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02514239","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03486067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03287908","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02064387","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03525678","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03544281","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03715478","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03848845","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01101594","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02728102","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03158688","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nina","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Aiello","sequence":"additional","affiliation":[{"name":"Patient Empowerment Network, San Jose, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Avigan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus G","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sarah Cannon Research Institute, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan M","family":"Borrello","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ganapathi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa","family":"Gray","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Green","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Multiple Myeloma Center for Clinical Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Manasanch","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C","family":"Munshi","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K","family":"Nooka","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P","family":"Rapoport","sequence":"additional","affiliation":[{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L","family":"Smith","sequence":"additional","affiliation":[{"name":"Myeloma Service and Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Siteman Cancer Center, Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"School of Medicine, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,12]]},"reference":[{"key":"2025100305205246000_8.2.e000734.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2025100305205246000_8.2.e000734.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104984"},{"key":"2025100305205246000_8.2.e000734.3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"2025100305205246000_8.2.e000734.4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"2025100305205246000_8.2.e000734.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"2025100305205246000_8.2.e000734.6","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000163","article-title":"Insights on multiple myeloma treatment strategies","volume":"3","author":"Mateos","year":"2019","journal-title":"Hemasphere"},{"key":"2025100305205246000_8.2.e000734.7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.25117","article-title":"Multiple myeloma: 2018 update on diagnosis, risk\u2010stratification, and management","volume":"93","author":"Rajkumar","year":"2018","journal-title":"Am J Hematol"},{"key":"2025100305205246000_8.2.e000734.8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/EDBK_200879","article-title":"Risk stratification and targets in multiple myeloma: from genomics to the bedside","volume":"38","author":"Perrot","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100305205246000_8.2.e000734.9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.seminoncol.2016.10.008","article-title":"A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"2025100305205246000_8.2.e000734.10","unstructured":"Biotech J . Daratumumab highlights of prescribing information. US: Food and Drug Administration, 2015."},{"key":"2025100305205246000_8.2.e000734.11","unstructured":"Squibb B-M . Highlights of prescribing information: EMPLICITI (elotuzumab) for injection, for intravenous use U.S. US: FDA, 2015."},{"key":"2025100305205246000_8.2.e000734.12","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100305205246000_8.2.e000734.13","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1200\/EDBK_200889","article-title":"Car T cells and other cellular therapies for multiple myeloma: 2018 update","volume":"38","author":"Cohen","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100305205246000_8.2.e000734.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793869"},{"key":"2025100305205246000_8.2.e000734.15","unstructured":"Harrington K et al . Development of JCARH125: optimization of a fully human Anti-Bcma CAR for use in the treatment of multiple myeloma 2017;130:1813."},{"key":"2025100305205246000_8.2.e000734.16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-Drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025100305205246000_8.2.e000734.17","doi-asserted-by":"crossref","unstructured":"Rakesh Popat NL , Trudel S , Voorhees PM , et al . B-Cell maturation antigen antibody-drug conjugate (ADC), GSK2857916, in relapsed\/refractory multiple myeloma (RRMM): final safety, efficacy and pharmacokinetic (pK) analyses from a phase I study, in 24th Congress of the European hematology association. Amsterdam: EHA Library, 2019.","DOI":"10.1097\/01.HS9.0000563764.80519.69"},{"key":"2025100305205246000_8.2.e000734.18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab Ravtansine (BT062) monotherapy in patients with relapsed and\/or refractory multiple myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025100305205246000_8.2.e000734.19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/08923973.2016.1153110","article-title":"Anti-Human CD138 monoclonal antibodies and their bispecific formats: generation and characterization","volume":"38","author":"Chen","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2025100305205246000_8.2.e000734.20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","article-title":"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (bite) immunotherapy, in R\/R multiple myeloma (Mm) patients: updated results of a first-in-human (FIH) phase I dose escalation study","volume":"37","author":"Topp","year":"2019","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci"},{"key":"2025100305205246000_8.2.e000734.22","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.3267","article-title":"Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial","volume":"4","author":"Nooka","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100305205246000_8.2.e000734.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-277137"},{"key":"2025100305205246000_8.2.e000734.24","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0188-z"},{"key":"2025100305205246000_8.2.e000734.25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo stratification of myeloma and Risk-Adapted therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2025100305205246000_8.2.e000734.26","doi-asserted-by":"crossref","unstructured":"Graham R . Clinical practice guidelines we can trust. Washington, DC: The National Academies Press, 2011: 290.","DOI":"10.17226\/13058"},{"key":"2025100305205246000_8.2.e000734.27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01228","article-title":"Daratumumab for the treatment of multiple myeloma","volume":"9","author":"Plesner","year":"2018","journal-title":"Front Immunol"},{"key":"2025100305205246000_8.2.e000734.28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194282"},{"key":"2025100305205246000_8.2.e000734.29","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112697","article-title":"Three-Year follow up of the phase 3 Pollux study of Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (RD) alone in relapsed or refractory multiple myeloma (RRMM)","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194118"},{"key":"2025100305205246000_8.2.e000734.31","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123483","article-title":"Four-Year follow-up of the phase 3 Pollux study of Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (RD) alone in relapsed or refractory multiple myeloma (RRMM)","volume":"134","author":"Kaufman","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"2025100305205246000_8.2.e000734.33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"2025100305205246000_8.2.e000734.34","doi-asserted-by":"crossref","unstructured":"Usmani SZ et al . Carfilzomib, dexamethasone, and Daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688). Blood 2019;134.","DOI":"10.1182\/blood-2019-132629"},{"key":"2025100305205246000_8.2.e000734.35","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-151","article-title":"Efficacy and updated safety analysis of a safety Run-in cohort from Griffin, a phase 2 randomized study of Daratumumab (DarA), bortezomib (V), lenalidomide (R), and dexamethasone (D; Dara\u2010Vrd) vs. Vrd in patients (PTS) with newly diagnosed (nd) multiple myeloma (Mm) eligible for High\u2010Dose therapy (HDT) and autologous stem cell transplantation (ASCT)","volume":"132","author":"Voorhees","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.36","article-title":"Daratumumab, Lenalidomide, Bortezomib, &amp; Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.37","first-page":"691","volume-title":"Depth of response to Daratumumab (DarA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (PTS) with Transplant-Eligible newly diagnosed multiple myeloma (NDMM): Griffin study update, in ash 2019","volume":"134","author":"Voorhees","year":"2019"},{"key":"2025100305205246000_8.2.e000734.38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DarA) in patients (PTS) with transplant-eligible (te) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS)","volume":"37","author":"Sonneveld","year":"2019","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"2025100305205246000_8.2.e000734.40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8003","article-title":"Phase 3 randomized study of daratumumab (DarA) + bortezomib\/thalidomide\/dexamethasone (D-VTd) vs VTd in transplant-eligible (te) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results","volume":"37","author":"Moreau","year":"2019","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.41","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100305205246000_8.2.e000734.42","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123401","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in Alcyone","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.43","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111065","article-title":"Phase 2 trial of Ixazomib, lenalidomide, dexamethasone and Daratumumab in patients with newly diagnosed multiple myeloma","volume":"132","author":"Kumar","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100305205246000_8.2.e000734.45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2142.2142","article-title":"Use of montelukast to reduce infusion reactions in an early access treatment protocol of Daratumumab in United States patients with relapsed or refractory multiple myeloma","volume":"128","author":"Chari","year":"2016","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1149.1149","article-title":"Open-Label, multicenter, dose escalation phase 1B study to assess the subcutaneous delivery of Daratumumab in patients (PTS) with relapsed or refractory multiple myeloma (PAVO)","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.47","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122765","article-title":"Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (Sc) versus intravenous (IV) Daratumumab (DarA) administration in patients with relapsed or refractory multiple myeloma: Columba update","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.48","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122501","article-title":"Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (Sc) versus intravenous (IV) Daratumumab (DarA) administration in patients (PTS) with relapsed or refractory multiple myeloma (RRMM): body weight subgroup analysis of Columba","volume":"134","author":"Mateos","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.49","unstructured":"Mateos MV . Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (Sc) versus intravenous (IV) daratumumab (DarA) administration in patients (PTS) with relapsed or refractory multiple myeloma (RRMM): Columba, in American Society of clinical oncology meeting. Chicago, US, 2019."},{"key":"2025100305205246000_8.2.e000734.50","unstructured":"al., C.A.e . Subcutaneous (Sc) Daratumumab (DarA) in combination with standard multiple myeloma (Mm) treatment regimens: an open-label, multicenter phase 2 study (PLEIADES), in 17th International myeloma workshop. Boston, MA, 2019: 24."},{"key":"2025100305205246000_8.2.e000734.51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000722"},{"key":"2025100305205246000_8.2.e000734.52","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/s41375-018-0120-2","article-title":"Ninety-minute daratumumab infusion is safe in multiple myeloma","volume":"32","author":"Barr","year":"2018","journal-title":"Leukemia"},{"key":"2025100305205246000_8.2.e000734.53","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12231212"},{"key":"2025100305205246000_8.2.e000734.54","first-page":"1866","article-title":"Activity and safety of Daratumumab Monotheray in patients with relapsed and refractory multiple myeloma requiring dialysis: preliminary results of Spanish, retrospective","volume":"130","author":"Cejalvo","year":"2017","journal-title":"Multicenter Trial"},{"key":"2025100305205246000_8.2.e000734.55","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.191122"},{"key":"2025100305205246000_8.2.e000734.56","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"2025100305205246000_8.2.e000734.57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.3745"},{"key":"2025100305205246000_8.2.e000734.58","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.3748\/wjg.v22.i28.6484","article-title":"Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy","volume":"22","author":"Law","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2025100305205246000_8.2.e000734.59","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12185-019-02685-z","article-title":"VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era","volume":"110","author":"Mizuta","year":"2019","journal-title":"Int J Hematol"},{"key":"2025100305205246000_8.2.e000734.60","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169235"},{"key":"2025100305205246000_8.2.e000734.61","doi-asserted-by":"publisher","DOI":"10.1373\/jalm.2018.026476"},{"key":"2025100305205246000_8.2.e000734.62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-848986"},{"key":"2025100305205246000_8.2.e000734.63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cca.2019.02.017","article-title":"Maldi-Tof mass spectrometry distinguishes daratumumab from M-proteins","volume":"492","author":"Moore","year":"2019","journal-title":"Clin Chim Acta"},{"key":"2025100305205246000_8.2.e000734.64","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/cclm-2015-0888","article-title":"Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)","volume":"54","author":"van de Donk","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2025100305205246000_8.2.e000734.65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with Anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front Immunol"},{"key":"2025100305205246000_8.2.e000734.66","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13789"},{"key":"2025100305205246000_8.2.e000734.67","doi-asserted-by":"crossref","unstructured":"Thomas Lin SH , Krey R , Pei H , et al . Daratumumab plus lenalidomide versus lenalidomide alone as maintenance treatment in patients with newly diagnosed multiple myeloma after frontline transplant: a multicenter, randomized, phase 3 study (AURIGA), in 17th International myeloma workshop. Boston, MA, 2019.","DOI":"10.1016\/j.clml.2019.09.332"},{"key":"2025100305205246000_8.2.e000734.68","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"2025100305205246000_8.2.e000734.69","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12532"},{"key":"2025100305205246000_8.2.e000734.70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"2025100305205246000_8.2.e000734.71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"},{"key":"2025100305205246000_8.2.e000734.72","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br J Haematol"},{"key":"2025100305205246000_8.2.e000734.73","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716652862"},{"key":"2025100305205246000_8.2.e000734.74","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8040","article-title":"Extended 5-y follow-up (Fu) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide\/dexamethasone (ELD) vs LD in relapsed\/refractory multiple myeloma (RRMM)","volume":"36","author":"Lonial","year":"2018","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.75","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100305205246000_8.2.e000734.76","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"2025100305205246000_8.2.e000734.77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"2025100305205246000_8.2.e000734.78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694604"},{"key":"2025100305205246000_8.2.e000734.79","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjh.14263","article-title":"Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed\/refractory multiple myeloma","volume":"175","author":"Mateos","year":"2016","journal-title":"Br J Haematol"},{"key":"2025100305205246000_8.2.e000734.80","doi-asserted-by":"crossref","first-page":"TPS8113","DOI":"10.1200\/jco.2012.30.15_suppl.tps8113","article-title":"ELOQUENT-1: a phase III, randomized, open-label trial of lenalidomide\/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006)","volume":"30","author":"Dimopoulos","year":"2012","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.81","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5600-x"},{"key":"2025100305205246000_8.2.e000734.82","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.62"},{"key":"2025100305205246000_8.2.e000734.83","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.976.976","article-title":"Phase II trial of combination of Elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"128","author":"Ghobrial","year":"2016","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.84","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115078","article-title":"Subsequent treatment outcomes of multiple myeloma refractory to CD38-Monoclonal antibody therapy","volume":"132","author":"Cornell","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.85","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115663","article-title":"Effect of timing of monoclonal antibody therapy on the time to next treatment and response rate in heavily pre-treated patients with myeloma who separately received both Daratumumab and Elotuzumab-Based regimens","volume":"132","author":"Becnel","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.86","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112246","article-title":"Natural history of patients with multiple myeloma refractory to Elotuzumab and outcomes of subsequent therapy with Anti-CD38 monoclonal antibodies","volume":"132","author":"Varnado","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.87","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/10428194.2019.1688324","article-title":"Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma","volume":"61","author":"Hoylman","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2025100305205246000_8.2.e000734.88","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ajh.24687","article-title":"A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 H, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma","volume":"92","author":"Berenson","year":"2017","journal-title":"Am J Hematol"},{"key":"2025100305205246000_8.2.e000734.89","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1373\/jalm.2016.020784","article-title":"Identification of Friend or foe: the laboratory challenge of differentiating M-proteins from monoclonal antibody therapies","volume":"1","author":"Mills","year":"2017","journal-title":"Jrnl App Lab Med"},{"key":"2025100305205246000_8.2.e000734.90","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1208\/s12248-016-9912-3","article-title":"Development and validation of electrochemiluminescence assays to measure free and total sSLAMF7 in human serum in the absence and presence of Elotuzumab","volume":"18","author":"Postelnek","year":"2016","journal-title":"Aaps J"},{"key":"2025100305205246000_8.2.e000734.91","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.2147\/OTT.S174640","article-title":"Update on elotuzumab for the treatment of relapsed\/refractory multiple myeloma: patients\u2019 selection and perspective]]&gt","volume":"12","author":"Trudel","year":"2019","journal-title":"OncoTargets and therapy"},{"key":"2025100305205246000_8.2.e000734.92","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.12.007"},{"key":"2025100305205246000_8.2.e000734.93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5414\/CNCS109165","article-title":"A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma","volume":"5","author":"Atchison","year":"2017","journal-title":"Clin Nephrol Case Stud"},{"key":"2025100305205246000_8.2.e000734.94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"2025100305205246000_8.2.e000734.95","doi-asserted-by":"crossref","unstructured":"Chari A et al . Phase Ib study of isatuximab+ carfilzomib in relapsed and refractory multiple myeloma (RRMM). American Society of Clinical Oncology, 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.8014"},{"key":"2025100305205246000_8.2.e000734.96","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0616"},{"key":"2025100305205246000_8.2.e000734.97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-02-895193"},{"key":"2025100305205246000_8.2.e000734.98","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8004","article-title":"A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"37","author":"Richardson","year":"2019","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8055"},{"key":"2025100305205246000_8.2.e000734.100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740787"},{"key":"2025100305205246000_8.2.e000734.101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2027"},{"key":"2025100305205246000_8.2.e000734.102","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13776"},{"key":"2025100305205246000_8.2.e000734.103","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)","volume":"24 Suppl 2","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025100305205246000_8.2.e000734.104","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e20005","article-title":"Risks of upper respiratory tract infection and pneumonia in patients with multiple myeloma receiving Daratumumab: a systematic review and meta-analysis of randomized controlled trials","volume":"36","author":"Ticona","year":"2018","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/EDBK_205443","article-title":"Practical considerations for antibodies in myeloma","volume":"38","author":"Laubach","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100305205246000_8.2.e000734.106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02204","article-title":"Checkpoint inhibition in myeloma: opportunities and challenges","volume":"9","author":"Costa","year":"2018","journal-title":"Front Immunol"},{"key":"2025100305205246000_8.2.e000734.107","doi-asserted-by":"crossref","unstructured":"Morandi F , Horenstein AL , Costa F , et al . Cd38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol 2018;9.doi:10.3389\/fimmu.2018.02722","DOI":"10.3389\/fimmu.2018.02722"},{"key":"2025100305205246000_8.2.e000734.108","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2018.014","article-title":"Elotuzumab for the treatment of relapsed or refractory multiple myeloma, with special reference to its modes of action and SLAMF7 signaling","volume":"10","author":"Taniwaki","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2025100305205246000_8.2.e000734.109","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v32.i4.10"},{"key":"2025100305205246000_8.2.e000734.110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00965"},{"key":"2025100305205246000_8.2.e000734.111","doi-asserted-by":"crossref","unstructured":"Cho S-F , Anderson KC , Tai Y-T . Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-Based immunotherapy. Front Immunol;9.doi:10.3389\/fimmu.2018.01821","DOI":"10.3389\/fimmu.2018.01821"},{"key":"2025100305205246000_8.2.e000734.112","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.77"},{"key":"2025100305205246000_8.2.e000734.113","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"2025100305205246000_8.2.e000734.114","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050"},{"key":"2025100305205246000_8.2.e000734.115","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.001"},{"key":"2025100305205246000_8.2.e000734.116","unstructured":"Corporation C . Celgene Corporation and bluebird bio announce bb2121 Anti-BCMA CAR-T cell therapy has been granted breakthrough therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma. Business Wire: businesswire.com, 2017."},{"key":"2025100305205246000_8.2.e000734.117","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"2025100305205246000_8.2.e000734.118","doi-asserted-by":"crossref","unstructured":"Deepu Madduri SZU , Sundar Jagannath IS , Zudaire E , et al . Results from CARTITUDE-1: a phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R Mm) in ASH2019. Orlando, FL: Blood, 2019.","DOI":"10.1182\/blood-2019-121731"},{"key":"2025100305205246000_8.2.e000734.119","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/17474086.2019.1617128","article-title":"Potential of NK cells in multiple myeloma therapy","volume":"12","author":"Khan","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"2025100305205246000_8.2.e000734.120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"key":"2025100305205246000_8.2.e000734.121","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, Anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a phase 1\/2 multicenter study (evolve)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.122","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124953","article-title":"Long-Term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (PTS) with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.123","unstructured":"European Medicines Agency . GrantsJanssenPRIME Designationfor JNJ-68284528(LCAR-B38M), an Investigational BCMA CAR-T Therapy Discovered by Legend Biotech. Johnson & Johnson, 2019."},{"key":"2025100305205246000_8.2.e000734.124","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-121731","article-title":"Results from CARTITUDE-1: a phase 1b\/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and\/or refractory multiple myeloma (R\/R Mm)","volume":"134","author":"Madduri","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.125","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkm446"},{"key":"2025100305205246000_8.2.e000734.126","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (Mm) (prime)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.127","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129405","article-title":"Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Cowan","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.128","first-page":"2838","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Normal lymphocytes"},{"key":"2025100305205246000_8.2.e000734.129","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"2025100305205246000_8.2.e000734.130","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.12.007"},{"key":"2025100305205246000_8.2.e000734.131","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12563"},{"key":"2025100305205246000_8.2.e000734.132","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127684","article-title":"Anti-Cd19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"4","author":"Garfall","year":"2019","journal-title":"JCI Insight"},{"key":"2025100305205246000_8.2.e000734.133","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025100305205246000_8.2.e000734.134","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131515","article-title":"Combination Anti-Bcma and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma","volume":"134","author":"Garfall","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.135","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504542"},{"key":"2025100305205246000_8.2.e000734.136","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116953"},{"key":"2025100305205246000_8.2.e000734.137","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human BCMA targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.138","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"2025100305205246000_8.2.e000734.139","unstructured":"Shalabi H et al . Intensification of Lymphodepletion optimizes CAR Re-Treatment efficacy 2017;130:3889."},{"key":"2025100305205246000_8.2.e000734.140","doi-asserted-by":"crossref","unstructured":"Abramson JS et al . High durable Cr rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-Directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort 2017;130:581.","DOI":"10.1002\/hon.2437_127"},{"key":"2025100305205246000_8.2.e000734.141","article-title":"Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine","author":"Elverum","year":"2019","journal-title":"Gene Ther"},{"key":"2025100305205246000_8.2.e000734.142","article-title":"Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)","volume":"130","author":"Cohen","year":"2017","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.143","unstructured":"U.S.F.a.D. administration . Kite, Yescarta package insert, 2017."},{"key":"2025100305205246000_8.2.e000734.144","unstructured":"U.S. FDA . Novartis, Kymriah package insert, 2017."},{"key":"2025100305205246000_8.2.e000734.145","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100305205246000_8.2.e000734.146","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of car T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100305205246000_8.2.e000734.147","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11899-019-0497-7","article-title":"Determination of minimal residual disease in multiple myeloma: does it matter?","volume":"14","author":"Kothari","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"2025100305205246000_8.2.e000734.148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568907"},{"key":"2025100305205246000_8.2.e000734.149","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am J Hematol"},{"key":"2025100305205246000_8.2.e000734.150","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/EDBK_205583","article-title":"Bones in multiple myeloma: imaging and therapy","volume":"38","author":"Zamagni","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100305205246000_8.2.e000734.151","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8024","article-title":"Early MRD negativity to predict deepening myeloma response in relapsed\/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells","volume":"36","author":"Munshi","year":"2018","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.152","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1585238"},{"key":"2025100305205246000_8.2.e000734.153","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.010","article-title":"Management principles associated with cytokine release syndrome","volume":"35","author":"Baer","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"2025100305205246000_8.2.e000734.154","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2025100305205246000_8.2.e000734.155","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100305205246000_8.2.e000734.156","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"2025100305205246000_8.2.e000734.157","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"2025100305205246000_8.2.e000734.158","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025100305205246000_8.2.e000734.159","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"2025100305205246000_8.2.e000734.160","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1629904"},{"key":"2025100305205246000_8.2.e000734.161","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"2025100305205246000_8.2.e000734.162","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"2025100305205246000_8.2.e000734.163","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"2025100305205246000_8.2.e000734.164","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"2025100305205246000_8.2.e000734.165","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.20"},{"key":"2025100305205246000_8.2.e000734.166","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7"},{"key":"2025100305205246000_8.2.e000734.167","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymthe.2016.11.011","article-title":"The Flipside of the power of engineered T cells: observed and potential toxicities of genetically modified T cells as therapy","volume":"25","author":"Bedoya","year":"2017","journal-title":"Mol Ther"},{"key":"2025100305205246000_8.2.e000734.168","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100305205246000_8.2.e000734.169","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25315"},{"key":"2025100305205246000_8.2.e000734.170","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djz017","article-title":"Car T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","author":"Hunter","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025100305205246000_8.2.e000734.171","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-019-0580-3"},{"key":"2025100305205246000_8.2.e000734.172","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2025100305205246000_8.2.e000734.173","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100305205246000_8.2.e000734.174","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"2025100305205246000_8.2.e000734.175","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760"},{"key":"2025100305205246000_8.2.e000734.176","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.311"},{"key":"2025100305205246000_8.2.e000734.177","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S151282"},{"key":"2025100305205246000_8.2.e000734.178","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.2.11221"},{"key":"2025100305205246000_8.2.e000734.179","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612"},{"key":"2025100305205246000_8.2.e000734.180","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0179"},{"key":"2025100305205246000_8.2.e000734.181","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS81","article-title":"Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed\/refractory multiple myeloma","volume":"36","author":"Richter","year":"2018","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.182","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2752"},{"key":"2025100305205246000_8.2.e000734.183","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1216"},{"key":"2025100305205246000_8.2.e000734.184","unstructured":"Amgen . Amgen Announces first-in-human data evaluating investigational novel BiTE\u00ae immunotherapies AMG 420 and AMG 330 at ash 2018, 2018."},{"key":"2025100305205246000_8.2.e000734.185","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-118425","article-title":"Anti-BCMA BiTE\u00ae AMG 701 potently induces specific T cell lysis of human multiple myeloma (Mm) cells and immunomodulation in the bone marrow microenvironment","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.186","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell Engager (TCE) CC-93269 in patients (PTS) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.187","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1200\/EDBK_159516","article-title":"New targets and new agents in high-risk multiple myeloma","volume":"35","author":"Nooka","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100305205246000_8.2.e000734.188","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"2025100305205246000_8.2.e000734.189","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"2025100305205246000_8.2.e000734.190","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.04.002"},{"key":"2025100305205246000_8.2.e000734.191","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0811036"},{"key":"2025100305205246000_8.2.e000734.192","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2013.87"},{"key":"2025100305205246000_8.2.e000734.193","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0547"},{"key":"2025100305205246000_8.2.e000734.194","unstructured":"Amgen . Highlights of prescribing information: blincyto\u00ae(blinatumomab) for injection for intravenous use, 2014."},{"key":"2025100305205246000_8.2.e000734.195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40264-018-0760-1","article-title":"Benefit-Risk assessment of Blinatumomab in the treatment of relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Stein","year":"2019","journal-title":"Drug Saf"},{"key":"2025100305205246000_8.2.e000734.196","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020198"},{"key":"2025100305205246000_8.2.e000734.197","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"2025100305205246000_8.2.e000734.198","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2147\/DDDT.S150317","article-title":"Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"12","author":"Yurkiewicz","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2025100305205246000_8.2.e000734.199","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"2025100305205246000_8.2.e000734.200","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"2025100305205246000_8.2.e000734.201","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6"},{"key":"2025100305205246000_8.2.e000734.202","doi-asserted-by":"crossref","unstructured":"Rakesh Popat JBO , Eliason L , Wilson J , et al . Amanda Bruno patient reported experience from Part 2 of the first time in human study of the BCMA antibody drug conjugate GSK2857916 for advanced relapsed refractory multiple myeloma (DREAMM-1), in 24th Congress of the European hematology association. Amsterdam: EHA Library, 2019.","DOI":"10.1097\/01.HS9.0000563880.66165.f1"},{"key":"2025100305205246000_8.2.e000734.203","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"2025100305205246000_8.2.e000734.204","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"2025100305205246000_8.2.e000734.205","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bcp.12988","article-title":"Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment","volume":"82","author":"Zhao","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025100305205246000_8.2.e000734.206","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4486.4486","article-title":"Indatuximab Ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or Pomalidomide: clinical activity in patients with relapsed \/ refractory multiple myeloma","volume":"128","author":"Kelly","year":"2016","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.207","unstructured":"AG B , Biotest AG . Immunogen has elected not to exercise its late stage co-development option for the US-Market with Biotest\"s antibody-drug conjugate (BT-062). Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG, 2017."},{"key":"2025100305205246000_8.2.e000734.208","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.09.002"},{"key":"2025100305205246000_8.2.e000734.209","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.018"},{"key":"2025100305205246000_8.2.e000734.210","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12565"},{"key":"2025100305205246000_8.2.e000734.211","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113910","article-title":"Results from the myeloproliferative neoplasm patient care survey: patient care opportunities and challenges","volume":"132","author":"Senyak","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.212","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JOP.18.00143","article-title":"Managing infusion reactions to new monoclonal antibodies in multiple myeloma: Daratumumab and Elotuzumab","volume":"14","author":"Nooka","year":"2018","journal-title":"J Oncol Pract"},{"key":"2025100305205246000_8.2.e000734.213","doi-asserted-by":"crossref","first-page":"42","DOI":"10.25270\/jcp.2018.10.00039","article-title":"Evolving the delivery of car T-cell therapies to the outpatient setting","volume":"4","author":"Smith","year":"2018","journal-title":"Journal of Clinical Pathways"},{"key":"2025100305205246000_8.2.e000734.214","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jamaoncol.2017.2148","article-title":"Out-Of-Pocket costs, financial distress, and underinsurance in cancer care","volume":"3","author":"Chino","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025100305205246000_8.2.e000734.215","unstructured":"Board, P.D.Q.A.T.E . Financial Toxicity and Cancer Treatment (PDQ(R)): Health Professional Version, in PDQ Cancer Information Summaries. National Cancer Institute (US: Bethesda (MD), 2002."},{"key":"2025100305205246000_8.2.e000734.216","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8016","article-title":"Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus RD alone: Maia","volume":"37","author":"Perrot","year":"2019","journal-title":"JCO"},{"key":"2025100305205246000_8.2.e000734.217","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112080","article-title":"Quality-Of-Life outcomes in patients with relapsed\/refractory multiple myeloma treated with Elotuzumab plus Pomalidomide and dexamethasone: results from the phase 2 randomized Eloquent-3 study","volume":"132","author":"Weisel","year":"2018","journal-title":"Blood"},{"key":"2025100305205246000_8.2.e000734.218","doi-asserted-by":"crossref","unstructured":"Surbhi Sidana AD , Burtis M , Griffin J , et al . Quality of life in patients undergoing chimeric antigen receptor (car) - t cell therapy vs. autologous and allogeneic stem cell transplant for hematologic malignancies, in 24th EHA Congress. Amsterdam: EHA Library, 2019.","DOI":"10.1097\/01.HS9.0000564264.01877.a2"},{"key":"2025100305205246000_8.2.e000734.219","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1261-6","article-title":"Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the myeloma patient outcome scale (MyPOS)","volume":"15","author":"Osborne","year":"2015","journal-title":"BMC Cancer"},{"key":"2025100305205246000_8.2.e000734.220","unstructured":"Tamara Syrek Jensen JC , Ashby LM , Hakim R , et al . Decision MEMO for chimeric antigen receptor (CAR) T-cell therapy for cancers CMS, 2019."},{"key":"2025100305205246000_8.2.e000734.221","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-Reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100305205246000_8.2.e000734.222","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5467-x","article-title":"Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study","volume":"19","author":"Parsons","year":"2019","journal-title":"BMC Cancer"},{"key":"2025100305205246000_8.2.e000734.223","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1548-y"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:21:27Z","timestamp":1759494087000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":223,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,12]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/jitc-2020-000734"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000734","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}